Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation
of Avanir Pharmaceuticals, Inc.
NEW YORK, Sept. 16, 2013
NEW YORK, Sept. 16, 2013 /PRNewswire/ -- Attorney Advertising --Bronstein,
Gewirtz & Grossman, LLC is investigating potential claims on behalf of
purchasers of the securities of Avanir Pharmaceuticals ("Avanir" or the
"Company") (NasdaqGS: AVNR). The investigation focuses on whether the Company
and its executives violated federal securities laws.
On September 11, 2013, shares of Avanir fell around 13% or $0.74 to close at
$4.79 after Gravity Research posted a report on the website Seeking Alpha,
alleging the following potential issues: illegal off-label marketing of
Nuedexta, a perceived likelihood of losing a patent case over the drug, and
possible financial difficulties. Shares of the Company closed on September
13, 2013 to trade at $4.08
If you are aware of any facts relating to this investigation, or purchased
shares of Avanir, you can assist this investigation by contacting either
Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of
Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email
email@example.com. Those who inquire by e-mail are encouraged to include their
mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our
primary expertise is the aggressive pursuit of litigation claims on behalf of
our clients. In addition to representing institutions and other investor
plaintiffs in class action security litigation, the firm's expertise includes
general corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not guarantee similar
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC
Press spacebar to pause and continue. Press esc to stop.